




RealRate

PHARMACEUTICAL 2022

Ernexa Therapeutics Inc
Rank 462 of 471



The relative strengths and weaknesses of Ernexa Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Ernexa Therapeutics Inc compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 8.1% points. The greatest weakness of Ernexa Therapeutics Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 132% points.

The company's Economic Capital Ratio, given in the ranking table, is 47%, being 228% points below the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	18,766
Cost of Goods Sold	0
Intangible Assets	2,044
Liabilities, Current	3,677
Liabilities, Non-Current	2,320
Other Assets	10,949
Other Compr. Net Income	0
Other Expenses	86,128
Other Liabilities	19,930
Other Net Income	-8,749
Other Revenues	0
Property and Equipment	670
Research and Development	12,705
Selling, General and Administrative Expense	14,724

Output Variable	Value in 1000 USD
Assets	32,429
Liabilities	25,927
Expenses	113,557
Revenues	0
Stockholders Equity	6,502
Net Income	-122,306
Comprehensive Net Income	-122,306
BaseVar	90,331
ECR before LimitedLiability	-371%
Economic Capital Ratio	47%